Kindly MD (NAKA)
NASDAQ:NAKA
Want to see NAKA full AI Analyst Report?
Top Page
Kindly MD
(NASDAQ:NAKA)
Select Model
Select Model
Rating:41Neutral
Price Target:
$0.19
▼(-27.31% Downside)
Action:UpgradedDate:03/31/26
The score is driven primarily by weak financial performance (declining revenue, deepening losses, and multi-year negative operating/free cash flow) and bearish technicals (price below key moving averages with negative MACD). Valuation provides limited offset because the company is loss-making (negative P/E) and no dividend yield is available.
Positive Factors
Strategic acquisitions expand revenue and capabilities
Acquiring BTC and UTXO brings a sizable, revenue-generating media/events business and high‑margin advisory income into the company. This materially diversifies revenue mix, adds recurring event/membership cash flows and distribution reach, and creates cross-sell opportunities that can sustainably improve top-line stability if integrated well.
Negative Factors
Persistent negative operating and free cash flow
Multi-year negative OCF and FCF indicate the business cannot reliably self-fund operations or growth. Continued cash burn forces dependence on external financing (equity or debt), limits ability to invest in product or sales, elevates refinancing and dilution risk, and makes execution of strategic plans fragile absent a durable cash‑flow turnaround.
Read all positive and negative factors
Positive Factors
Negative Factors
Strategic acquisitions expand revenue and capabilities
Acquiring BTC and UTXO brings a sizable, revenue-generating media/events business and high‑margin advisory income into the company. This materially diversifies revenue mix, adds recurring event/membership cash flows and distribution reach, and creates cross-sell opportunities that can sustainably improve top-line stability if integrated well.
Read all positive factors
Kindly MD (NAKA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$131.79M
Dividend YieldN/A
Average Volume (3M)30.98M
Price to Earnings (P/E)0.5
Beta (1Y)4.12
Revenue Growth-33.04%
EPS Growth-44.86%
CountryUS
Employees23
SectorHealthcare
Sector Strength45
IndustryMedical - Equipment & Services
Share Statistics
EPS (TTM)-0.26
Shares Outstanding690,018,250
10 Day Avg. Volume32,220,503
30 Day Avg. Volume30,978,537
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.14
Price to Sales (P/S)38.59
P/FCF Ratio-0.10
Enterprise Value/Market Cap1.96
Enterprise Value/Revenue142.10
Enterprise Value/Gross Profit-27.93
Enterprise Value/Ebitda-5.76
Forecast
1Y Price Target
$0.75Price Target Upside188.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.02
Revenue Forecast (FY)$46.60M
Kindly MD Business Overview & Revenue Model
Company Description
Nakamoto Inc. develops and invests in a global portfolio of Bitcoin-native companies. The company provides commercial and financial infrastructure for the capital markets. The company was formerly known as Kindly MD, Inc. and change its name to Na...
How the Company Makes Money
null...
Kindly MD Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
41
Neutral
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.82M | 2.72M | 3.77M | 3.79M | 2.50M |
| Gross Profit | -9.27M | 2.64M | -264.17K | -595.29K | 914.92K |
| EBITDA | -44.93M | -3.00M | -1.36M | -2.42M | 124.74K |
| Net Income | -52.23M | -3.62M | -1.62M | -2.54M | 149.34K |
Balance Sheet | |||||
| Total Assets | 730.61M | 3.68M | 1.10M | 947.00K | 447.64K |
| Cash, Cash Equivalents and Short-Term Investments | 22.58M | 2.27M | 525.50K | 186.92K | 94.69K |
| Total Debt | 209.56M | 783.68K | 636.38K | 391.13K | 109.81K |
| Total Liabilities | 216.35M | 1.11M | 1.21M | 565.98K | 174.56K |
| Stockholders Equity | 514.26M | 2.57M | -108.41K | 381.01K | 273.09K |
Cash Flow | |||||
| Free Cash Flow | -719.99M | -3.48M | -463.91K | -457.77K | 57.84K |
| Operating Cash Flow | -23.51M | -3.07M | -449.49K | -140.38K | 121.44K |
| Investing Cash Flow | -680.02M | -401.63K | -14.42K | -317.39K | -63.60K |
| Financing Cash Flow | 723.85M | 5.22M | 802.49K | 550.00K | -45.34K |
Kindly MD Technical Analysis
Neutral
0.26
Price Trends
0.25
Positive
0.34
Negative
2.79
Negative
Market Momentum
>-0.01
Negative
59.43
Neutral
82.23
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NAKA, the sentiment is Neutral. The current price of 0.26 is above the 20-day moving average (MA) of 0.23, above the 50-day MA of 0.25, and below the 200-day MA of 2.79, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 59.43 is Neutral, neither overbought nor oversold. The STOCH value of 82.23 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for NAKA.
Kindly MD Risk Analysis
Kindly MD disclosed 135 risk factors in its most recent earnings report. Kindly MD reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Kindly MD Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | $1.68B | 63.77 | 2.44% | 6.98% | 5.62% | -20.89% | |
63 Neutral | $1.70B | -10.55 | -28.85% | ― | ― | -33.82% | |
54 Neutral | $455.42M | -5.08 | -23.00% | ― | 57.87% | 7.83% | |
53 Neutral | $1.87B | -9.32 | -269.56% | ― | 550.00% | -107.76% | |
52 Neutral | $1.16B | -5.61 | -88.31% | ― | -27.50% | -36.74% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
41 Neutral | $131.79M | 0.47 | -20.84% | ― | -33.04% | -44.86% |
* Healthcare Sector Average
NAKA
Kindly MD
0.19
-2.87
-93.76%
EYPT
EyePoint Pharmaceuticals
13.85
7.60
121.60%
INBX
Inhibrx Biosciences Inc
127.95
115.51
928.54%
RAPP
Rapport Therapeutics, Inc.
35.53
25.14
241.96%
SILA
Sila Realty Trust, Inc.
30.43
6.20
25.61%
BBNX
Beta Bionics, Inc.
10.22
-1.13
-9.96%
Kindly MD Corporate Events
Business Operations and StrategyFinancial DisclosuresM&A Transactions
Kindly MD completes all-stock acquisition and equity issuance
Positive
Feb 26, 2026
On February 20, 2026, Nakamoto Inc. closed all-stock mergers to acquire BTC Inc., a global Bitcoin media and events operator, and UTXO Management GP, a Bitcoin-focused investment adviser, making both entities wholly owned subsidiaries. The transac...
Financial DisclosuresM&A TransactionsRegulatory Filings and Compliance
Kindly MD Updates Merger Targets’ Revenue and EBITDA Figures
Neutral
Feb 19, 2026
On February 18, 2026, Nakamoto CEO and Chairman David Bailey used an X Space hosted by Bitcoin Magazine to discuss the pending mergers with BTC Inc. and UTXO Management GP, LLC, and to clarify earlier revenue commentary. He acknowledged that his p...
Business Operations and StrategyM&A Transactions
Kindly MD announces major stock-based acquisition agreements
Positive
Feb 17, 2026
On February 16, 2026, Nakamoto Inc. exercised its option to acquire BTC Inc. and UTXO Management and signed definitive merger agreements that will make both targets wholly owned subsidiaries. The all-stock transaction, valued at about $107.3 milli...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.